Is neratinib/neratinib a targeted therapy?

Neratinib/Neratinib (Neratinib) is an anti-cancer drug clearly classified as "targeted therapy" and is mainly used for the extended treatment of HER2-positive breast cancer. In the field of cancer treatment, targeted therapy refers to intervention strategies targeting specific molecular targets. Neratinib is an irreversible panHER tyrosine kinase inhibitor (TKI) that acts on the human epidermal growth factor receptor family. It can inhibit the activities of three receptors, HER1, HER2 and HER4, at the same time. Unlike traditional chemotherapy drugs, it does not directly kill all rapidly dividing cells, but precisely "turns off" the molecular signaling pathways that cancer cells rely on for survival and expansion, with higher selectivity and relatively better tolerance.

The mechanism of action of neratinib is based on breast cancer in which HER2 receptor is overexpressed or gene amplified. HER2 is a protein that promotes cell growth. About 20% of breast cancer patients are HER2-positive, and the disease progresses faster and has a higher risk of metastasis. Neratinib prevents further proliferation and escape of cancer cells by blocking HER2-related signals. It is especially used for HER2-positive patients who have already received trastuzumab (Herceptin) treatment as an extended adjuvant treatment in order to reduce the risk of recurrence.

It is worth noting that neratinib is not limited to breast cancer indication research, but also shows potential in multiple HER2-positive solid tumors, including gastric cancer, biliary tract tumors, and colorectal cancer. This expansion of the scope of indications also further strengthens its targeting properties as a multi-target pan-HER inhibitor. International guidelines and multiple clinical studies have included neratinib in the adjuvant treatment regimen for HER2-positive breast cancer, especially for patients who have previously responded to trastuzumab but are at high risk of recurrence.

Reference materials:https://en.wikipedia.org/wiki/Neratinib